



October 13, 2022

Jiany Zhang

(b) (6)

Sent via email to: (b) (6)

Dear Petitioner:

Your submission requesting that the Commissioner to issue approval of using combined Potential Therapeutic Drugs to treat Alzheimer's disease was received and processed under CFR 10.30 by this office on 10/13/2022.

It was assigned docket number FDA-2022-P-2516. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note, the acceptance of the petition for filing is a procedural matter and in no way reflects the Agency's decision on the substantive merits of the petition.

Sincerely,

Karen Malvin  
Acting Director  
Dockets Management Staff  
FDA/Office of Operations (OO)

U.S. Food & Drug Administration  
10903 New Hampshire Avenue, Silver Spring, MD 20993  
[www.fda.gov](http://www.fda.gov)